Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1644
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18257444 | ANTIBODIES SPECIFIC FOR QSOX1 AND METHODS OF USING THE SAME | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18464580 | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 17627085 | ANTIBODIES AGAINST HUMAN TREM-1 AND USES THEREOF | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 17286203 | Combination Therapy for Melanoma | Non-Final OA | Bristol-Myers Squibb Company |
| 18308899 | NOVEL CELLULAR RECEPTORS AND USES THEREOF | Non-Final OA | TRUSTEES OF BOSTON UNIVERSITY |
| 18261414 | CD27-EXTRACELLULAR DOMAIN CAR TO TARGET CD70-POSITIVE TUMORS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18175049 | ALLOGENEIC THERAPEUTIC CELLS | Non-Final OA | Kite Pharma, Inc. |
| 18167438 | METHODS OF SENSITIZING CANCER TO IMMUNOTHERAPY | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 17631830 | T CELL RECEPTORS AND METHODS OF USE THEREOF | Final Rejection | University Health Network |
| 18451576 | Probiotic-Guided CAR-T Cells for Tumor Targeting | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 17291959 | CHIMERIC ANTIGEN RECEPTOR MEMORY-LIKE (CARML) NK CELLS AND METHODS OF MAKING AND USING SAME | Non-Final OA | Washington University |
| 17050231 | COMPOSITIONS AND METHODS FOR TREATING ABDOMINAL AORTIC ANEURYSM | Non-Final OA | University of Virginia Patent Foundation |
| 17614786 | IMMUNOGENIC COMPOSITIONS | Final Rejection | Telethon Kids Institute |
| 17178595 | ANTI-HER2 POLYPEPTIDES AND METHODS OF USE THEREOF | Final Rejection | Denali Therapeutics Inc. |
| 18698856 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | Non-Final OA | Maddon Advisors LLC |
| 17499012 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | Final Rejection | Maddon Advisors LLC |
| 17634968 | NOVEL LOX-1 ANTIBODY COMPOSITIONS, LOX1 NEUTRALIZATION ASSAY AND METHODS OF TREATMENT USING SAME | Non-Final OA | The Wistar Institute of Anatomy and Biology |
| 17921042 | TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR | Final Rejection | Merus N.V. |
| 17263675 | METHOD FOR PRODUCING CD3-POSITIVE CELL | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18266125 | ANTI-EGFR NANOBODY AND USE THEREOF | Non-Final OA | SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. |
| 18271883 | IMPROVED ADOPTIVE CELL TRANSFER THERAPY FOR CANCER | Non-Final OA | Hadasit Medical Research Services and Development Ltd. |
| 17636373 | NOVEL ANTI-CLDN18.2 ANTIBODIES | Non-Final OA | TRANSCENTA THERAPEUTICS, INC. |
| 17606523 | COMBINATION OF HER2 ANTIBODIES | Final Rejection | MAB DISCOVERY GMBH |
| 17042855 | VISTA ANTIGEN-BINDING MOLECULES | Non-Final OA | Hummingbird Bioscience Holdings Pte. Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy